Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company. Co.'s pipeline has two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are chemical entities discovered in-house. Co.'s primary drug candidate, RP5063, is for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis. Furthermore, RP5063 is for two respiratory indications,?pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Co.'s RP1208 is for the indication of depression and obesity. The RVPH stock yearly return is shown above.
The yearly return on the RVPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RVPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|